Gemzar
Phase 3Small molecule
Eli LillyGemzar is one of 176 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 3.
5
Indications
11
Total Trials
1
Active Trials
175
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
Eli LillyPhase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer5 trials
ZN-c3 + Gemcitabine in Pancreatic Cancer
Active, not recruiting·—·Phase 2·NCT06015659·12 enrolled
Cancer of the Pancreas1 trial
2 more indications
Cervical Cancer1 trial
Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
Unknown status·—·Phase 3·NCT00842660·172 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemzar. EMBL-EBI & Wellcome Sanger Institute.
- [4]